In this study, obesity was associated with an increased risk of breast cancer recurrence among postmenopausal patients with HR+ early-stage breast cancer treated with aromatase inhibitors. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.